7-methylxanthine for slowing childhood myopia progression
Childhood myopia (short-sightedness) is a rapidly growing global chronic disease, with severe cases leading to sight-threatening complications due to axial elongation of the eyeball. Research is focusing on interventions like 7-methylxanthine to slow this progression, as early treatment before age 16 is critical to prevent high myopia and long-term visual impairment.
Why it matters
Myopia is a leading cause of preventable blindness, and effective treatments to slow its progression could significantly improve global public health and quality of life for millions of children.
Childhood myopia (short-sightedness) has become one of the fastest growing chronic diseases worldwide. As the prevalence of high myopia (severe short-sightedness) continues to rise, research is exploring approaches that address the biological mechanisms driving axial elongation.
Myopia is a progressive eye condition in which the eyeball becomes too long or the cornea too curved, causing the light to focus in front of the retina. While genetics can contribute, the dramatic rise in global myopia is largely driven by environmental factors, particularly reduced time outdoors and exposure to sunlight, as well as increased screen use.
Childhood myopia (short-sightedness) has become one of the fastest growing chronic diseases worldwide.
Recognised as the leading cause of preventable blindness, the condition is estimated to affect nearly 50 percent of the global population, with approximately 1 billion people expected to develop myopia greater than -5.00 diopters by 2050. 1
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in